论文部分内容阅读
人类狂犬病感染仍是一个主要的公共卫生问题,每年死亡人数达2万多人。现行的疫苗仍是神经组织疫苗,虽经改进,但接种程序长而麻烦,且不能提供安全的、无副反应的保护作用。两年前问世的廉价的新一代狂犬病纯化疫苗为狂犬病流行的不发达国家中狂犬病免疫接种的革新带来了希望。这种疫苗提供的保护作用与人二倍体细胞疫苗相仿。设计一种合适的人类狂犬病免疫接种技术包括新的接种方案,其中之一是改进的肌肉接种方案,仅需4剂疫苗分3次接种,并证实对接触后处理高度有效。
Human rabies infection remains a major public health problem, killing more than 20,000 people each year. The current vaccine is still a nerve tissue vaccine, although improved, but the vaccination process is long and troublesome, and can not provide safe, no side effects of the protective effect. The new, affordable, next-generation rabies vaccine that came out two years ago offers the promise of a revolution in rabies vaccination in under-developed rabies-endemic countries. The vaccine provides protection similar to human diploid cell vaccines. Designing a suitable human rabies immunization technology includes a new vaccination program, one of which is an improved muscular inoculation regimen that requires only 4 doses of the vaccine to be inoculated in 3 replicates and demonstrates that it is highly effective in contact post-treatments.